Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Positive effects of nuclear medicine, ’smart drugs’ provide hope for non-hodgkin’s lymphoma patients

22.06.2005


Researchers from the United States, France and Germany make advances, provide alternatives to traditional chemotherapy treatment



Three scientific studies--each highlighting new discoveries in treatment for patients with non-Hodgkin’s lymphoma--were announced at the Society of Nuclear Medicine’s 52nd Annual Meeting June 18–22 in Toronto.

"Nuclear medicine has a growing role in treating non-Hodgkin’s lymphoma," said SNM member Richard L. Wahl, M.D., director of nuclear medicine/PET at the Russell H. Morgan Department of Radiology and Radiological Science. "When nuclear medicine is used earlier in the course of the illness, there is a higher efficacy of treatment," he added. In "An Update of Complete Response Durability Following Tositumomab and Iodine I-131 Tositumomab (the Bexxar® Therapeutic Regimen) in a Pivotal Study of Patients (PTS) Refractory to Their Last Chemotherapy," the findings suggest "that we may have changed the course of the disease," said Wahl.


According to the results of that 2001 "pivotal" study, 60 patients, who had been previously treated with and had failed to respond or responded poorly to multiple types of chemotherapy--and whose tumors had recurred--received a single course of treatment with a radioactive antibody or "smart drug" injected into the bloodstream that targets and kills cancer cells, he explained. Of those patients, 65 percent responded to treatment; 20 percent had complete response or no evidence of remaining cancer. In the initial report, those complete responders were over 47 months. Four years later, the update study revealed that those patients who achieved a complete response had "an enduring response," noted Wahl, indicating that "while we can’t say the patients are ’cured,’ they have lived without the disease recurring for a substantial period of their lives."

With the therapeutic regimen, a patient receives an injected test dose of the antitumor monoclonal antibody-- tositumomab and iodine I-131 tositumomab--to determine how his or her body processes that tagged antibody. Nuclear medicine imaging scans assess how quickly the drug reaches the tumor and how quickly radiation disappears from a patient’s body. The dose given to each patient is individualized to the patient’s own handling of the drug, so the patient receives a "personalized dose" of the treatment. Therapy is considered complete after the patient receives that individualized therapeutic dose, typically one week or so after the dosimetric dose. "We have achieved an impressive response rate from a single dose of therapy," said Wahl. "We can adjust the dose, depending on how it behaves in a person," he added, saying, "Nuclear medicine has a clear effect on lymphoma."

The current standard course of treatment for lymphoma is intensive chemotherapy. Patients receive chemotherapy every three weeks over a time period of up to six months. This treatment has unpleasant side effects, including nausea, hair loss and infections. With the nuclear medicine treatment, patients find that the most common side effect is a temporary lowering of blood counts for several weeks. Patients are now offered a choice of "months of chemotherapy or a tracer and treatment dose given over about a week," said Wahl.

Results are even more promising using tositumomab and iodine-131 tositumomab earlier in the course of the illness before many chemotherapies have failed. "Efficacy by Treatment Course Following Tositumomab and Iodine I-131 Tositumomab (the Bexxar® Therapeutic Regimen) and Chemotherapy" showed that while response and duration of response to the radioactive antibody treatment declined with each chemotherapeutic encounter, the radioactive antibody treatment "produced response rates and durations that exceeded those following chemotherapy," said Wahl. Earlier this year, the use of this form of treatment in previously untreated patients with non-Hodgkin’s lymphoma was reported to show a 95 percent response rate, suggesting this form of treatment should be considered earlier in the course of the illness, he noted.

Non-Hodgkin’s lymphoma is a cancer of the lymphatic system, the body’s blood-filtering tissues that help to fight infection and disease. A variety of factors including congenital and acquired immunodeficiency states--as well as infectious, physical and chemical agents--have been associated with an increased risk of developing non-Hodgkin’s lymphoma. This year, more than 56,000 new cases of non-Hodgkin’s lymphoma will be detected and more than 19,000 deaths will occur in the United States, according to cancer experts. This cancer of the immune system became more familiar to the general public as it struck celebrities such as Jackie Kennedy Onassis, baseball great Roger Maris and King Hussein of Jordan.

Investigators from France and Germany studied a new form of radioimmunotherapy that utilizes a humanized monoclonal antibody against the CD22 tumor marker expressed by non-Hodgkin’s lymphoma cells. Investigators used a specific antibody, which mainly consists of human material, to carry a potent radioisotope because the internalizing properties of the antibody are particularly suited to selectively localizing the radiation in the lymphoma cells, according to the results of "Fractionated Radioimmunotherapy in NHL With DOTA-Conjugated, Humanized Anti-CD22 Epratuzumab at High Cumulative 90Y Doses."

"Fractionated radioimmunotherapy (RIT) is feasible and our data suggest better safety results than bolus RIT, since patients appear to tolerate higher doses of therapy. Such radioimmunotherapy methods and reagents should expand the opportunities for the therapy of blood-type cancers and encourage our pursuit of this nuclear medicine technology for the treatment of more therapy-resistant solid cancer," said Jean-Francois Chatal, M.D., with the Institut de Biologie, INSERM, Nantes, France. "This multicenter trial is also evaluating the safety and efficacy of this agent in a continuing dose-escalation trial," added the SNM member.

Chatal commented, "Radioimmunotherapy has already been introduced into the management of indolent non-Hodgkin’s lymphoma patients with Zevalin® and Bexxar®. We are encouraged by the results of a humanized antibody targeting a different target of non-Hodgkin’s lymphoma cells that may be particularly effective with a therapeutic radiometal." He continued, "Since the antibody is humanized, we chose to give it repeatedly, in smaller doses than the regimen used by the other two products, with the aim of making it more tolerable and possibly more effective. So far, the high cumulative dose levels that have been achieved--and the very encouraging clinical results--both appear to support our idea."

"These three studies represent significant advances and future trends in therapy for patients with non-Hodgkin’s lymphoma," said Lale Kostakoglu, M.D., vice chair of the SNM Scientific Program Committee’s Oncology/Hematology Track and an associate professor at Cornell University’s Weill Medical School who is also on staff in the department of radiology, division of nuclear medicine, at New York Presbyterian Hospital.

Maryann Verrillo | EurekAlert!
Further information:
http://www.snm.org

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>